In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $420.41, a high estimate of $570.00, and a low estimate of $333.00.

The US Food and Drug Administration approved the revised label for inclisiran, a small interfering RNA that reduces the ...

The FDA has approved a labeling update for Leqvio (inclisiran) allowing for first-line use in the treatment of hypercholesterolemia.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord Genuity 45th Annual Growth ...

Researchers introduced the PREVENT risk age equations to help determine risk of cardiovascular disease. (JAMA Cardiology) A ...

The US Food and Drug Administration (FDA) has approved a label update for Swiss pharma giant Novartis’ Leqvio (inclisiran), ...

The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

Novartis announced the FDA approved updated labeling for inclisiran, a small-interfering RNA therapy, for use as monotherapy ...

Note that some links may require registration or subscription. Justin Timberlake said he has been diagnosed with Lyme disease ...

Shares of European pharmaceutical companies sold off on Friday after President Donald Trump sent letters to 17 companies, including U.S. firms, in the sector.

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low ...